Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO
Cardio Diagnostics — Investor Presentation (August 2026)
24 slides from Cardio Diagnostics's investor presentation, Aug 20, 2026
Slide 1: Leading the Next Frontier in Precision Cardiovascular Medicine
Leading the Next Frontier in Precision Cardiovascular Medicine 2026 NASDAQ: CDIO 1 Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Act of 1995 . When used in this presentation, the word
Slide 2: Forward-Looking Statements and Disclaimers
“will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Such statements are subj
Slide 3: Commercial Lifecycle of Diagnostic Tests
Commercial Lifecycle of Diagnostic Tests 3 Scientific Validatio n Regulatory Requirement s Reimbursemen t and Coverage Physician Adoption and Clinical Guidelines Behavioral and Workflow Integration
Slide 4: Toward a World Where Cardiovascular Disease Isn't the #1 Killer
Toward a World Where Cardiovascular Disease Isn’t the #1 Killer Our Mission: To make cardiovascular disease prevention and early detection more accessible, personalized and precise. Our Vision: Precision cardiovascular medicine, powered by artificial intelligence and multi - modal technologies , tra
Slide 5: Corporate Highlights
To our knowledge, we have developed the first and only commercial solutions leveraging epigenetics and AI for cardiovascular disease prevention and early detection Strong and growing pipeline supported by ongoing studies and new product development Robust IP portfolio Diversified US and internationa
Slide 6: Leadership
President, Nutex Health, Inc. (NUTX) Co - founder of Astrana Health (ASTH) Director and former CEO of Clinigence Holdings (CLNH) MD from Georgetown University School of Medicine Warren Hosseinion, MD Leadership CEO & Director Co - founder of Cardio Diagnostics Co - inventor of the AI - Driven Multi
Slide 7: Cardiovascular Disease Remains the Leading Cause of Death Globally Despite Being Largely Preventable
⁽ ¹ ⁾ American Heart Association ⁽ ² ⁾ CDC ⁽ ³ ⁾ World Health Organization (4) Kaiser Family Foundation, 2024 ~35K Only about 35,000 c ardiologists are practicing in the US, far short of the growing demand for cardiovascular care (4) $2T Following a healthy lifestyle may prevent ~80% of premature ca
Slide 8: The Burden of Cardiovascular Disease is Immense and Growing
⁽ ¹ ⁾ American Heart Association ⁽ ² ⁾ Haidar, A et al., The American Journal of Cardiology Jan 2025, /doi.org/10.1016/j.amjcard.2024.10.003 ⁽ ³ ⁾ CDC Employers Patients In the US, he art disease is responsible for approximately 920,000 deaths in 2023, which equates to 1 in every 3 deaths ⁽ ¹ ⁾ Card
Slide 9: Multi-Omics: Epigenetics + Genes = An Individual's Unique Molecular Fingerprint
GENETICS (SINGLE NUCLEOTIDE POLYMORPHISMS) (1) Sum heritability from Hou, K et al., Nature Genetics Aug 2019, /doi.org/10.1038/S41588 - 019 - 0465 - 0 Multi - Omics: Epigenetics + Genes = An Individual’s Unique Molecular Fingerprint • Inherited from parents • <20% of risk for cardiovascular disease
Slide 10: Our AI-Driven Multi-Omics Engine Turns Molecular Fingerprints Into Actionable Clinical Insights
Our Engine, designed and built over 14+ years, provides a scalable foundation for sustained product expansion, clinical impact, and long - term value creation Data • High - quality clinical and molecular samples and database • Ongoing studies for interventions and new modalities Identification of Ro
Slide 11: Beyond Multi-Omics: A More Complete Picture of Cardiovascular Health
Beyond Multi - Omics: A More Complete Picture of Cardiovascular Health The platform we’re building: a detection and monitoring platform that catches cardiovascular risk and disease earlier and with high precision, tracks how each patient’s profile changes over time, and matches patients to intervent
Slide 12: IP Portfolio: Patents, Trade Secrets & Proprietary Assets
PATENT FAMILIES Detecting Predisposition to CVD Predicting & Monitoring CVD Diabetes Prediction & Monitoring Algorithm for Determining Mortality IP Portfolio: Patents, Trade Secrets & Proprietary Assets TRADE SECRETS & PROPRIETARY ASSETS Digital Healthcare Dashboard AI Platform Proprietary Reagents
Slide 13: Cardio Diagnostics' AI-Powered Clinical Tests
Cardio D iagnostics’ AI - Powered Clinical Tests Risk Stratification ⁽ ¹ ⁾ Diagnostic Aid ⁽ ² ⁾ To our knowledge, Epi+Gen CHD is the first and only commercially available blood test capable of assessing the three - year risk of a coronary heart disease event, including a heart attack To our knowledg
Slide 14: Epi+Gen CHD Risk Stratification Test
Epi+Gen CHD R isk Stratification Test (Rx Only) cost savings per quality adjusted life year (QALY) ⁽ ³ ⁾ Up to $42K ⁽ ¹ ⁾ Internal estimate ⁽ ² ⁾ Dogan et al., 2021 Epigenomics ⁽ ³ ⁾ Jung Y et al., 2021, Epigenomics - cost savings were not calculated for a specific payer compared to the average sens
Slide 15: PrecisionCHD Diagnostic Aid Test
PrecisionCHD D iagnostic Aid Test (Rx Only) cost savings in the first year if PrecisionCHD used as the primary method of initial CHD assessment for one million lives ⁽ ³ ⁾ ~$113M ⁽ ¹ ⁾ Internal estimate ⁽ ² ⁾ Philibert et al., 2023 JAHA ⁽ ³ ⁾ Frisvold D et al., 2024, Advances in Therapy - cost savin
Slide 16: Our Tests Offer a Scalable, Novel Approach for Cardiovascular Disease Prevention and Detection
The use of Epi+Gen CHD and PrecisionCHD could save lives and reduce costs associated with cardiovascular disease Our Tests Offer a Scalable, Novel Approach for Cardiovascular Disease Prevention and Detection Not one and done Fast and convenient First - of - its - kind No exposure to ionizing radiati
Slide 17: Clinical Validation and Study Pipeline
Clinical validations: rigorous studies in partnership with leading health systems Economic evidence: demonstrating cost effectiveness and cost savings Monitor treatment effectiveness: evidence demonstrating the utility of the tests INOCA detection: u se of PrecisionCHDTM to detect non - obstructive
Slide 18: A Highly Scalable Testing and Reporting Process
2a 2b 1a 1b REMOTE Telemedicine provider orders test for patient At - home lancet sample collection kit shipped to patient A Highly Scalable Testing and Reporting Process PROVIDER SETTINGS Lancet and/or vacutainer sample collection kits shipped to provider/healthcare organization Provider/healthcare
Slide 19: In-House Test Processing Has Begun in Our Company-Owned CLIA Lab
Survey found no deficiencies; state licenses (CA, MD, PA, RI) obtained CLIA conditions met Expand research efforts for ongoing and future studies in precision monitoring of cardiovascular health Expand r esearch studies Space to increase infrastructure and automation to increase capacity Increased t
Slide 20: Epi+Gen CHD and PrecisionCHD US Market Opportunity
Ep i+Gen CHD and PrecisionCHD US Market Opportunity ~40% target gross margin at scale 20 ⁽ ¹ ⁾ Internal estimate TAM was calculated by multiplying the CMS final gapfill rate with the estimated Americans eligible for the test. Price for te st can vary for patients and organizations. Market opportunit
Slide 21: Commercial Targets in the US
Commercial Targets in the US Employers/Unions Offering remote and heart health fair options to drive engagement and utilization among employees Telemedicine and onsite options primarily with internists, PCPs and preventive cardiologists Providers and Health Systems Channel Partners Strategic partner
Slide 22: Opportunistic Global Expansion Through Partnerships
Opportunistic Global Expansion Through Partnerships Partnership progress in India with Aimil Ltd and Dr. Lal PathLabs Aimil to introduce PrecisionCHD to their extensive healthcare network Exploring other partner - led international expansion opportunities in Asia, Middle East and Africa 22 In active
Slide 23: Major Reimbursement Milestones Achieved and Underway for Both Tests
1 Major Reimbursement Milestones Achieved and Underway for Both Tests 23 COMPLETED CPT PLA Code Assigned (January 2024) 0439U: Epi+Gen CHDTM 0440U: PrecisionCHDTM COMPLETED CMS Final Payment Rate Set (December 2025) $854 per test (both codes) In - Network Coverage (June 2026) Atlas Healthcare Physic
Slide 24: For more information, please email investors@cdio.ai
For more information, please email: investors@cdio.ai 24
Cardio Diagnostics Holdings — Investor Presentation (August 2026) on 6ix